Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $4,178,454.06 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 227,337 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $18.38, for a total value of $4,178,454.06. Following the sale, the director owned 8,511 shares in the company, valued at approximately $156,432.18. The trade was a 96.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $17.39 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The business’s 50-day simple moving average is $17.89 and its 200 day simple moving average is $18.53. The company has a market cap of $2.87 billion, a P/E ratio of -4.91 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.02). On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently made changes to their positions in the company. Hilton Head Capital Partners LLC bought a new stake in shares of Dyne Therapeutics in the 1st quarter valued at approximately $26,000. Chung Wu Investment Group LLC bought a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $30,000. Strs Ohio bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at approximately $84,000. Finally, Steward Partners Investment Advisory LLC increased its holdings in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on DYN. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Morgan Stanley dropped their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Chardan Capital restated a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, HC Wainwright dropped their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $35.14.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.